

Printed as of 4/19/2024

Disclosures

Self C&C BioPharma,	Ltd.	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies		
	Ltd.	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies		
				Heart Failure and Cardiomyopathies		
Additional	Personal Comme	ercial Disclosures for Education Activities	5 (0)			
	No disclosures on record					
Non-Commercial Enity Name Self		Relationship Category	Compensation Level	Topic Area(s)		
NIH Grant		Research/Research Grants	Significant (>= \$5,000)			

Expert Witness Testimony (9)

No disclosures on record

/ear	Case Title	Represented	Description	Compensation
Self				
2020	Heart disease and smoking	Defendant † Shook Hardy and Bacon	Contribution of cardiovascular disease to cause of death	Modest (< \$5,000)
2019	Heart disease and smoking	Defendant † Shook Hardy and Bacon	Contribution of cardiovascular disease to cause of death	Modest (< \$5,000)
2018	Cardiovascular risk	Defendant † Shook Hardy and Bacon	Contribution of cardiovascular disease to cause of death	Modest (< \$5,000)
2017	Product Liability	Defendant † Shook Hardy and Bacon LLP	Advised clients on extent of tobacco-related injuries.	Significant (>= \$5,000)
2016	Product Liability	Defendant † Hughes Hubbard and Reed LLP	Advised clients on extent of tobacco-related injuries.	Modest (< \$5,000)
2016	Product Liability	Defendant † Shook Hardy and Bacon, LLP	Advised clients on extent of tobacco-related injuries.	Significant (>= \$5,000)
2015	Tobacco Product Liability	Defendant † Shook Hardy and Bacon LLP	Advised clients on extent of tobacco-related injuries.	Significant (>= \$5,000)
2014	Tobacco product liability	Defendant † Shook Hardy and Bacon LLP	Advised client about the likelihood that plaintiff's injuries resulted from chronic smoking.	Significant (>= \$5,000)
2013	Tobacco liability	Defendant	Advised client about the likelihood that plaintiff's injuries resulted from chronic smoking.	None (\$0)

† Commercial Funding Source | *‡* Trial Name

Agreement

Certified Education Attestation | Signed on 10/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/17/2023 URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

On-Going Obligation Agreement | Signed on 10/17/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.